Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
AgomAb Therapeutics sets its IPO price at $16 per American depositary share, aiming to raise funds for debt repayment and corporate expenses. The biotech firm focuses on immunology and inflammatory diseases, testing market demand alongside other recent IPOs.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.